Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture

por Isakov, Ofer, Wallis, Deeann, Evans, D. Gareth, Ben-Shachar, Shay
Publicado 2018

Affinity Purification of NF1 Protein–Protein Interactors Identifies Keratins and Neurofibromin Itself as Binding Partners

por Carnes, Rachel M., Kesterson, Robert A., Korf, Bruce R., Mobley, James A., Wallis, Deeann
Publicado 2019

Behavioral and transcriptomic profiling of mice null for Lphn3, a gene implicated in ADHD and addiction

por Orsini, Caitlin A., Setlow, Barry, DeJesus, Michael, Galaviz, Stacy, Loesch, Kimberly, Ioerger, Thomas, Wallis, Deeann
Publicado 2016

Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C

por Awad, Elias K., Moore, Marc, Liu, Hui, Ciszewski, Lukasz, Lambert, Laura, Korf, Bruce R., Popplewell, Linda, Kesterson, Robert A., Wallis, Deeann
Publicado 2021

Functional Genomics Screening Utilizing Mutant Mouse Embryonic Stem Cells Identifies Novel Radiation-Response Genes

por Loesch, Kimberly, Galaviz, Stacy, Hamoui, Zaher, Clanton, Ryan, Akabani, Gamal, Deveau, Michael, DeJesus, Michael, Ioerger, Thomas, Sacchettini, James C., Wallis, Deeann
Publicado 2015

Mutation-Directed Therapeutics for Neurofibromatosis Type I

por Leier, Andre, Bedwell, David M., Chen, Ann T., Dickson, George, Keeling, Kim M., Kesterson, Robert A., Korf, Bruce R., Marquez Lago, Tatiana T., Müller, Ulrich F., Popplewell, Linda, Zhou, Jiangbing, Wallis, Deeann
Publicado 2020

Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I

por Leier, André, Moore, Marc, Liu, Hui, Daniel, Michael, Hyde, Alexis M., Messiaen, Ludwine, Korf, Bruce R., Selvakumaran, Jamuna, Ciszewski, Lukasz, Lambert, Laura, Foote, Jeremy, Wallace, Margaret R., Kesterson, Robert A., Dickson, George, Popplewell, Linda, Wallis, Deeann
Publicado 2022

Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13

por Aggarwal, Anup, Parai, Maloy K., Shetty, Nishant, Wallis, Deeann, Woolhiser, Lisa, Hastings, Courtney, Dutta, Noton K., Galaviz, Stacy, Dhakal, Ramesh C., Shrestha, Rupesh, Wakabayashi, Shoko, Walpole, Chris, Matthews, David, Floyd, David, Scullion, Paul, Riley, Jennifer, Epemolu, Ola, Norval, Suzanne, Snavely, Thomas, Robertson, Gregory T., Rubin, Eric J., Ioerger, Thomas R., Sirgel, Frik A., van der Merwe, Ruben, van Helden, Paul D., Keller, Peter, Böttger, Erik C., Karakousis, Petros C., Lenaerts, Anne J., Sacchettini, James C.
Publicado 2017

ADGRL3 (LPHN3) variants predict substance use disorder

por Arcos-Burgos, Mauricio, Vélez, Jorge I., Martinez, Ariel F., Ribasés, Marta, Ramos-Quiroga, Josep A., Sánchez-Mora, Cristina, Richarte, Vanesa, Roncero, Carlos, Cormand, Bru, Fernández-Castillo, Noelia, Casas, Miguel, Lopera, Francisco, Pineda, David A., Palacio, Juan D., Acosta-López, Johan E., Cervantes-Henriquez, Martha L., Sánchez-Rojas, Manuel G., Puentes-Rozo, Pedro J., Molina, Brooke S. G., Boden, Margaret T., Wallis, Deeann, Lidbury, Brett, Newman, Saul, Easteal, Simon, Swanson, James, Patel, Hardip, Volkow, Nora, Acosta, Maria T., Castellanos, Francisco X., de Leon, Jose, Mastronardi, Claudio A., Muenke, Maximilian
Publicado 2019